Surgery Partners (SGRY) director lifts stake to 68,093 shares
Rhea-AI Filing Summary
Surgery Partners, Inc. (SGRY) director Teresa DeLuca reported an amended insider purchase of 11,250 shares of common stock on August 18, 2026 at a weighted average price of $14.33 per share. Following this transaction, she beneficially owns 68,093 shares directly. The amendment corrects an earlier Form 4 that had understated both the shares purchased and the price per share.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 11,250 shares
Net Buy
1 txn
Insider
DeLuca Teresa
Role
Director
Bought
11,250 shs ($161K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock F1, F2 | 11,250 | $14.33 | $161K |
Holdings After Transaction:
Common Stock — 68,093 shares (Direct)
Footnotes (2)
- F1. The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price.
- F2. This Form 4/A amends the Form 4 originally filed on August 19, 2026 to correct the number of shares of the Issuer's common stock purchased by the Reporting Person and the purchase price per share reported in Table I. The original Form 4 inadvertently reported the purchase of 10,000 shares at a price of $14.35 per share. The Reporting Person actually purchased 11,250 shares at a price of $14.33 per share. The amount of securities beneficially owned following the transaction has been corrected accordingly. Except as set forth herein, the original Form 4 remains unchanged.
Key Figures
Shares purchased: 11,250 shares
Weighted average purchase price: $14.33 per share
Shares beneficially owned after transaction: 68,093 shares
+2 more
5 metrics
Shares purchased
11,250 shares
Common stock purchased on August 18, 2026
Weighted average purchase price
$14.33 per share
Price for the 11,250 common shares purchased
Shares beneficially owned after transaction
68,093 shares
Direct ownership following the August 18, 2026 purchase
Original shares reported (now corrected)
10,000 shares
Amount originally reported before this amendment
Original reported price (now corrected)
$14.35 per share
Original price per share reported in the prior Form 4
Key Terms
Form 4/A, weighted average price, beneficially owned, Rule 10b5-1
4 terms
Form 4/A regulatory
"This Form 4/A amends the Form 4 originally filed on August 19, 2026"
Form 4/A is an amended filing that corrects or updates an earlier Form 4, the mandatory report that insiders (like company executives, directors, or large shareholders) must file when their ownership stakes change. Think of it as an edited receipt showing who bought or sold stock and when; investors use it to track insider confidence, detect potential conflicts, and spot trading patterns that might signal future company prospects.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
beneficially owned financial
"The amount of securities beneficially owned following the transaction has been corrected"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
Rule 10b5-1 regulatory
"aff_10b5_one is the filing's document-level Rule 10b5-1 checkbox"
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.
FAQ
What insider transaction did SGRY director Teresa DeLuca report on this Form 4/A?
She reported purchasing 11,250 shares of Surgery Partners, Inc. common stock on August 18, 2026 in an open market or private transaction, at a weighted average price of $14.33 per share, as corrected in this amended filing.
What was corrected in this amended Form 4/A for SGRY?
The amendment states that the original Form 4 had reported a purchase of 10,000 shares at $14.35 per share, but the reporting person actually purchased 11,250 shares at $14.33 per share. The beneficial ownership amount after the transaction was also corrected.
Was the SGRY insider purchase by Teresa DeLuca under a Rule 10b5-1 trading plan?
No. The filing’s Rule 10b5-1 checkbox is not marked as affirmatively relying on a trading plan, and there is no footnote indicating that the reported purchase was made pursuant to a Rule 10b5-1 trading arrangement.
AI-generated analysis. How Rhea-AI works. Not financial advice.
